迪安诊断
(300244)
| 流通市值：84.45亿 | | | 总市值：105.25亿 |
| 流通股本：5.01亿 | | | 总股本：6.25亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,936,484,994.33 | 2,365,125,686.41 | 12,196,223,734.01 | 9,258,110,867.57 |
| 营业收入 | 4,936,484,994.33 | 2,365,125,686.41 | 12,196,223,734.01 | 9,258,110,867.57 |
| 二、营业总成本 | 4,643,502,517.31 | 2,246,966,921.12 | 11,403,545,691.66 | 8,491,254,006.48 |
| 营业成本 | 3,574,366,089.38 | 1,740,876,331.02 | 8,779,606,550.03 | 6,661,093,418.77 |
| 税金及附加 | 19,542,576.9 | 10,168,333.59 | 43,325,165.81 | 29,421,498.33 |
| 销售费用 | 534,126,852.74 | 258,905,714.22 | 1,217,768,951.79 | 876,607,622.37 |
| 管理费用 | 329,307,750.23 | 136,784,132.2 | 858,931,870.6 | 547,061,712.54 |
| 研发费用 | 116,121,837.11 | 57,443,584.55 | 305,880,933.28 | 225,278,980.27 |
| 财务费用 | 70,037,410.95 | 42,788,825.54 | 198,032,220.15 | 151,790,774.2 |
| 其中:利息费用 | 76,731,696.59 | 42,786,490.45 | 203,027,893.07 | 155,361,651.96 |
| 其中:利息收入 | 12,421,807.74 | 3,941,698.06 | 25,668,594.64 | 19,408,685.41 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,353,507.97 | 2,565,031.54 | -12,696,720.83 | -15,805,135.25 |
| 加:投资收益 | 10,703,242.12 | -6,532,709.05 | 38,712,506.27 | 9,184,435.86 |
| 资产处置收益 | 1,181,965.86 | -774,268.67 | -1,476,191.11 | 2,478,187.96 |
| 资产减值损失(新) | -169,884.86 | -1,414,134.43 | -401,578,630 | 767,410.38 |
| 信用减值损失(新) | -215,301,292.37 | -100,237,182.78 | -483,449,219.1 | -354,350,039.84 |
| 其他收益 | 19,102,935.98 | 11,657,758.55 | 36,695,034.82 | 26,715,565.6 |
| 四、营业利润 | 115,852,951.72 | 23,423,260.45 | -31,115,177.6 | 435,847,285.8 |
| 加:营业外收入 | 3,092,202.94 | 263,034.82 | 11,348,915.49 | 7,838,016.37 |
| 减:营业外支出 | 8,145,477.49 | 2,972,696.75 | 32,059,988.7 | 19,513,681.76 |
| 五、利润总额 | 110,799,677.17 | 20,713,598.52 | -51,826,250.81 | 424,171,620.41 |
| 减:所得税费用 | 28,596,901.51 | 16,541,322.46 | 117,406,845.49 | 121,487,823.69 |
| 六、净利润 | 82,202,775.66 | 4,172,276.06 | -169,233,096.3 | 302,683,796.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 82,202,775.66 | 4,172,276.06 | -169,233,096.3 | 302,683,796.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 10,277,234.44 | -21,005,565.65 | -357,277,652.58 | 130,856,888.98 |
| 少数股东损益 | 71,925,541.22 | 25,177,841.71 | 188,044,556.28 | 171,826,907.74 |
| 扣除非经常损益后的净利润 | -9,235,485.89 | -26,305,778.11 | -380,108,163.92 | 134,148,310.25 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | -0.03 | -0.58 | 0.21 |
| (二)稀释每股收益 | 0.02 | -0.03 | -0.58 | 0.21 |
| 八、其他综合收益 | - | - | 20,871.95 | -1,679.5 |
| 归属于母公司股东的其他综合收益 | - | - | 20,871.95 | -1,679.5 |
| 九、综合收益总额 | 82,202,775.66 | 4,172,276.06 | -169,212,224.35 | 302,682,117.22 |
| 归属于母公司股东的综合收益总额 | 10,277,234.44 | -21,005,565.65 | -357,256,780.63 | 130,855,209.48 |
| 归属于少数股东的综合收益总额 | 71,925,541.22 | 25,177,841.71 | 188,044,556.28 | 171,826,907.74 |
| 公告日期 | 2025-08-21 | 2025-04-29 | 2025-04-23 | 2024-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |